Status:
COMPLETED
Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
Lead Sponsor:
Fatima Maqsood
Conditions:
Diabetes Mellitus
Heart Failure
Eligibility:
All Genders
40-60 years
Phase:
NA
Brief Summary
Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily. A...
Detailed Description
This study's rationale is to examine the effects of dapagliflozin and empagliflozin on heart failure in patients receiving ARNI and SGLT2. Research revealed that the two medications results are identi...
Eligibility Criteria
Inclusion
- Patients aged 40-60 years of either gender diagnosed with heart failure ( Heart failure was defined as presence of ejection fraction \<50% on echocardiography, with pedal edema, water in lungs, paroxysmal nocturnal dyspnea or exertional limitation due to failure of ventricular fillings)
- Diabetic patients, with HBA1c\>6.5% for \>1 year already taking SGLT-2 and ARNI inhibitor.
Exclusion
- Patients already had valvular device, mitral or aortic valve regurgitation or stenosis detected on echocardiography, heart transplantation, chronic renal failure or dialysis patients, cardiomyopathy, liver failure or malignancy.
- Patients already taking trial drugs or other anti-glycemic or cardiac medication.
Key Trial Info
Start Date :
July 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2025
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT06915870
Start Date
July 12 2024
End Date
January 13 2025
Last Update
April 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaikh Zayed Hospital
Lahore, Punjab Province, Pakistan, 54600